60 DEGREES PHARMACEUTICALS, INC.
SXTPDrugs in Pipeline
1
Phase 3 Programs
0
Upcoming Catalysts
1
Next Catalyst
Next month
Market Overview
Stock performance and key metrics
1 upcoming, 0 past
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Tafenoquine | Phase 2 | Healthy Volunteers | - | - |
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in 60 DEGREES PHARMACEUTICALS, INC.'s drug pipeline?→
CatalystAlert tracks 1 drug candidate in 60 DEGREES PHARMACEUTICALS, INC.'s (SXTP) pipeline across Phase 2. Its lead program is Tafenoquine (Phase 2). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is 60 DEGREES PHARMACEUTICALS, INC.'s next FDA catalyst?→
60 DEGREES PHARMACEUTICALS, INC.'s (SXTP) next tracked catalyst is a Earnings expected November 12, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track SXTP biotech catalysts?→
Add SXTP to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow 60 DEGREES PHARMACEUTICALS, INC.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.